Cargando…
APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty
OBJECTIVES: The clinical utility of conventional IV opioids is limited by the occurrence of opioid‐related adverse events. Oliceridine is a novel G protein–biased μ‐opioid receptor agonist designed to provide analgesia with an improved safety and tolerability profile. This phase III, double‐blind, r...
Autores principales: | Singla, Neil K., Skobieranda, Franck, Soergel, David G., Salamea, Monica, Burt, David A., Demitrack, Mark A., Viscusi, Eugene R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851842/ https://www.ncbi.nlm.nih.gov/pubmed/31162798 http://dx.doi.org/10.1111/papr.12801 |
Ejemplares similares
-
APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy
por: Viscusi, Eugene R, et al.
Publicado: (2019) -
A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty
por: Singla, Neil, et al.
Publicado: (2017) -
Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults
por: Lambert, David, et al.
Publicado: (2020) -
Can oliceridine (TRV130), an ideal novel µ receptor G protein pathway selective (µ-GPS) modulator, provide analgesia without opioid-related adverse reactions?
por: Ok, Hwoe Gyeong, et al.
Publicado: (2018) -
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine
por: Nafziger, Anne N., et al.
Publicado: (2019)